Ожирение

Study links prediabetes remission to lower diabetes risk without weight loss

Researchers in Tübingen have found that people with prediabetes can reduce their risk of developing type 2 diabetes by 71% through lifestyle changes that normalize blood sugar levels, even if they do not lose weight. The study emphasizes the role of improved fat distribution over mere weight reduction. This challenges current guidelines focused primarily on shedding pounds.

Study highlights disparities in obesity care access

4 октября 2025 Сообщено ИИ

A recent analysis reveals significant gaps in obesity treatment for certain demographic groups in the United States. Researchers found that access to care varies widely based on race, income, and location, underscoring ongoing challenges in healthcare equity.

Higher semaglutide dose boosts weight loss in obesity trials

5 октября 2025 Сообщено ИИ

Two phase 3 clinical trials show that a 7.2 mg weekly dose of semaglutide leads to greater weight loss than the approved 2.4 mg dose in adults with obesity, including those with type 2 diabetes. Nearly half of participants on the higher dose lost 20% or more of their body weight over 72 weeks. The results, published in The Lancet Diabetes & Endocrinology, suggest improved metabolic health with a favorable safety profile.

Конец патентной защиты для инъекций для снижения веса принесет пользу пациентам

3 октября 2025 Сообщено ИИ

Патентная защита семаглутида в инъекциях для снижения веса, таких как Оземпик и Вегови, истекает в Европе. Это открывает путь для более дешевых дженериков на рынок и может снизить высокие цены. Пациенты с ожирением выиграют от улучшенного доступа.

Scientists discover protein that switches off hunger